Blindspot Capital

Blindspot Capital

By by FemmeHealth AllianceBusinessEntrepreneurship
Download on the App Store

Blindspot Capital episodes

  • She Coined ‘FemTech’. Now She’s Rewriting the Narrative on Women’s Health

    What if naming something was the first step to making it investable?

    In this episode of Blindspot Capital, I sit down with Ida Tin, entrepreneur, systems thinker, and the woman who coined the term FemTech. She’s also the co-founder and former CEO of Clue, one of the most widely used women’s health apps in the world, with over 10 million active users in 190+ countries.

    But this conversation isn’t just about legacy. It’s about language, legitimacy, and the long game of funding women’s health.

    We cover:

    🟣 How FemTech started as a bridge to help male investors care

    🟣 What naming a category unlocked and unintentionally limited

    🟣 The persistent bias that keeps women’s health boxed in as “niche”

    🟣 The mindset shift from founder to systems-change leader

    🟣 Why we believe women’s health is infrastructure

    🟣 What she’s building next with Femtech Assembly and why she’s doing it differently

    Join 10,000+ readers of the FemmeHealth newsletter on Substack.

    --------------------------

    FEMTECH Assembly

    --------------------------

    Why You Should Listen:

    If you’re a founder, investor, or operator navigating digital health, this is the truth-telling conversation you won’t hear on stage. No fluff. Just data, capital dynamics, and the patterns no one’s naming.

    📌 Watch full episode on YouTube



    Get full access to The Billion Dollar Blindspot at blog.billiondollarblindspot.com/subscribe
    29 min
  • Why Most Digital Health Startups Will Fail

    Half the headlines in healthcare are hype. But what if we stopped chasing the next shiny thing and started fixing the fundamentals?

    In this episode of Blindspot Capital, I sit down with Sergei Polevikov, mathematician, investor, and co-host of the podcast Digital Health Inside Out, to talk about what’s broken in digital health from copycat AI startups to gender bias in funding and where we should be paying attention instead.

    In This Episode We Cover:

    🟣 Why most digital health startups are chasing performance signals that don’t matter🟣 The VC paradox: how underperforming funds still raise while women founders get ignored🟣 The rise of “AI tourists” in healthcare and why most won’t survive🟣 What investors are missing in autoimmune, menopause, and cardiovascular health🟣 How women-led companies often outperform and still get passed over🟣 What needs to change in how capital flows are structured🟣 Why Sergei and Alex launched Digital Health Inside Out and what he's learning from clinicians, not conferences.

    Join 10,000+ readers of the FemmeHealth newsletter on Substack.

    ----------------------------------------------------

    🎙️ Sergei and Alex’s podcast: Digital Health Inside Out📬

    Sergei’s Substack: AI Health Uncut

    ----------------------------------------------------

    Why You Should Listen:

    If you’re a founder, investor, or operator navigating digital health, this is the truth-telling conversation you won’t hear on stage. No fluff. Just data, capital dynamics, and the patterns no one’s naming.

    📌 Watch full episode on YouTube



    Get full access to The Billion Dollar Blindspot at blog.billiondollarblindspot.com/subscribe
    31 min
  • What Real Science in Women’s Health Looks Like

    Half the population experiences these conditions. Many are universal, recurring, and clinically significant. Yet in the eyes of too many investors, women’s health therapeutics remain “optional.”

    In this episode of Blindspot Capital, I sit down with Sabrina Johnson, President & CEO of Daré Bioscience, to unpack the misconceptions holding back investment in women’s health from contraception to menopause to vaginal health and explore how disciplined science can change the game.

    In This Episode We Cover:

    🟣 Why women’s health markets are larger and more recurrent than most investors realize

    🟣 The false perception that women’s health conditions are “lifestyle” or “optional”

    🟣 The reality of recruiting participants for women’s health trials (and why stigma isn’t a barrier)

    🟣 What scientific credibility really looks like in biotech and how to protect it

    🟣 The difference between medicine and marketing and why the distinction matters for investors

    🟣 Why angel investors have a leadership opportunity in women’s health

    Join 10,000+ readers of the FemmeHealth newsletter on Substack.

    ------------------------------

    Why You Should Listen If you care about women’s health, biotech, or the intersection of science and capital, this is a clear-eyed look at the market opportunities hiding in plain sight and the leadership it will take to unlock them.

    About Sabrina Johnson Sabrina Johnson is the President & CEO of Daré Bioscience, a biopharmaceutical company driven by a mission to challenge the status quo, making women's health a priority. Daré believes that innovation does not have to start from scratch.

    The company’s goal is to bring to market as soon as practicable innovative evidence-based solutions that address decades of unmet needs in women’s health and enhance outcomes and convenience, primarily in the areas of contraception, sexual health, pelvic pain, fertility, infectious disease, vaginal health and menopause. Learn more Here

    🎧 Listen now and share with someone who still thinks women’s health is “niche.”

    📌 Watch on YouTube



    Get full access to The Billion Dollar Blindspot at blog.billiondollarblindspot.com/subscribe
    26 min
  • A Drop of Blood That Could Save Millions: The Future of Preeclampsia Diagnosis

    In this episode, healthcare investor and strategist Maryann Umoren Selfe is joined by Matthias Wipf, CEO of Swiss medtech company MOMM Diagnostics, to examine the systemic gaps in how we identify and fund life-saving healthcare infrastructure for women.

    🟣 Why preeclampsia remains one of the most dangerous, misunderstood pregnancy complications

    🟣 What point-of-care diagnostics like Pre-Exclude are doing differently

    🟣 Why diagnostics in women’s health are underfunded and what that reveals about investor psychology

    🟣 How preeclampsia connects to long-term cardiovascular risk 🟣 What’s holding back innovation in maternal health and how to change it

    🟣 Why investing in maternal health benefits not just women, but entire health systems

    Join 10,000+ readers of the FemmeHealth newsletter on Substack.

    ------------------

    About MOMM Diagnostics:Founded in 2018, MOMM Diagnostics is reimagining maternal care with préXclude, a breakthrough test for early detection of preeclampsia. With just a drop of blood and a few minutes, their technology gives clinicians the power to act before pregnancy complications become emergencies. Born out of research collaborations in Switzerland and California, MOMM is part of a new wave of founders who are turning overlooked health problems into high-impact innovation. Learn more here.



    Get full access to The Billion Dollar Blindspot at blog.billiondollarblindspot.com/subscribe
    27 min
  • Blind Spot Capital is Here!

    Blind Spot Capital Podcast Trailer

    Welcome to Blind Spot Capital, the podcast where health innovation meets investment insight. Every year, investors bet billions on the future of health but most still miss one of the biggest opportunities in the market: women’s health.

    You tell a woman to “wait and see” while her organ shuts down? That’s not medicine. That’s neglect.

    We talk to the founders building what should have existed, the investors backing what's next, and the strategists reshaping the capital stack before it’s too late.Subscribe now. New episodes every other Thursday.🎧 Available on Spotify, Apple, Substack, and YouTube.



    Get full access to The Billion Dollar Blindspot at blog.billiondollarblindspot.com/subscribe
    2 min
  • Episode #6: This Startup Is Changing the Way We Detect Cervical Cancer

    A few weeks ago, Ronald Vos and Nutte van Belzen, the founders of CC Diagnostics were at a major European medical congress when they were approached by a woman who didn’t work in science or medicine. She had bought an expensive delegate ticket, not to participate in the conference, but to seek help.

    She had advanced cervical cancer. And she came in the hope that someone…anyone, at this gathering of gynaecologists and scientists might listen to her story and offer a lifeline.

    “We hope all those cases can be prevented,” co-founder Nutte van Belzen reflects.

    That moment captures exactly why this episode matters.

    Only 15% of women participate in cervical screenings, despite the fact that cervical cancer is entirely preventable through early detection and vaccination. The problem? Existing methods are invasive, uncomfortable, and all too easy to avoid until it’s too late.

    In this conversation, the founders of CC Diagnostics share their journey: the personal experience and passion that fuels their mission, the technology they are building to make self-sampling accessible, and their vision for a world where diagnostics are not a privilege, but a right.

    We also dive into:

    * The overlooked challenges of building a diagnostics company.

    * Why many investors hesitate and why that needs to change.

    * Their roadmap for global access, including a pricing model for low- and middle-income countries (LMICs).

    This isn’t just a conversation about tech or start-ups.

    It’s about the human stories that push innovation forward, and the urgent need to act before another woman buys a ticket to beg for care.

    🎧 Watch the full episode for a powerful and personal look at how we can, and must, do better in women’s health.

    CC Diagnostics

    CC Diagnostics (Netherlands) offers a clinically validated screening test, significantly improving cervical cancer detection rates to 97% (vs current market benchmark of 76%). Our product offers a 6x reduction in time per test for the diagnostic labs, dramatically reducing costs and improving efficiency. Our Methica test technology enables screening from home (with self-sampled material), unlocking a broader €5.5Bn screening market worldwide. We achieved commercial progress, with the first 2 international orders from leading CLIA labs in the US and UK.

    CC Diagnostics (Netherlands)



    Get full access to The Billion Dollar Blindspot at blog.billiondollarblindspot.com/subscribe
    34 min
  • Episode #5: Transforming PostPartum Care with AI

    In this conversation, Maryann and Astrid Gyllenkrok, CEO and Co-Founder of LEIA Health discuss the challenges of parenthood, particularly focusing on the postpartum experience and the need for better support systems for new parents.

    Astrid shares her journey in founding LEIA, a Swedish startup on a mission to support the next one billion parents by digitising the parental journey, offering AI-powered support at a time when parents need it the most.

    They explore the importance of personalized education, the role of employers in supporting parental leave, and the challenges faced by women entrepreneurs in the health sector. The discussion emphasizes the need for advocacy, funding, and systemic change to improve the experiences of parents and promote women's health.

    Astrid has been named Female Entrepreneur of the Year in Sweden and LEIA has been named One of Europes’ hottest startups by both Sifted, Wired and Business Insider. As a mother of three she's passionate about women's health and changing the narrative around parental health.

    -----------

    Mamma app | LEIA | Stockholm



    Get full access to The Billion Dollar Blindspot at blog.billiondollarblindspot.com/subscribe
    53 min
  • Episode #4: Breaking Barriers in Drug Delivery for Women

    In this episode of FemmeHealth Founders, Maryann speaks with Dr. Lara Zibners, co-founder of Calla Lily Clinical Care, about the inadequacies in current drug delivery methods for women's health. Lara shares her personal journey from being a physician to an entrepreneur, driven by her own experiences with infertility and the challenges of existing treatments.

    With a broad background in clinical medicine and medical education in both the US and UK, Lara brings a unique understanding to Calla Lily of the scientific, systematic and business challenges facing women’s healthcare.

    -----------

    Current methods of vaginal drug delivery are profoundly inadequate for millions of women around the world. Calla Lily has developed a new leak-free vaginal drug delivery platform. It's simple to use (essential when patients have to administer medications themselves) and also helps to alleviate dosage anxiety and other stresses.

    Innovators in Vaginal Drug Delivery | Calla Lily Clinical Care



    Get full access to The Billion Dollar Blindspot at blog.billiondollarblindspot.com/subscribe
    32 min
  • Episode #3 - The Story Behind OvulaRing

    In this episode of Notes to Selfe, we dive into the fascinating world of women's health innovation with Sebastian Alexander, founder and CEO of VivoSensMedical. We explore the journey of OvulaRing, a groundbreaking technology transforming the way we understand and address female fertility and gynaecological diagnostics.

    From the legacy of Sebastian's father-in-law, a pioneer in IVF and reproductive medicine, to the challenges of building a company in an underfunded and often overlooked sector, this episode is a deep dive into the realities of advancing women's health.

    Together, we discuss:

    * The unmet needs in women's reproductive health.

    * How core body temperature is revolutionising fertility diagnostics.

    * The gender data gap in healthcare and why it matters.

    * The importance of patient capital in driving women's health innovation.

    * How value-aligned investors can play a pivotal role in transforming the future of women's health.

    If you are an investor, founder, or simply someone passionate about advancing healthcare for women, this episode will inspire and inform you.

    ----------

    VivoSensMedical GmbH is a young, medical company from Leipzig that combines medical-scientific experience, technical know-how, marketing and sales expertise, and management practice. The company's vision is to transfer a wealth of experience of over 40 years of scientific work in clinical and user-friendly products to benefit both patients and doctors. VivoSensMedical strives to set new standards in diagnosis and treatment in the fields of gynaecology, reproductive and sexual medicine, and immunology and autoimmune diseases.

    vivosensmedical.com

    OvulaRing cycle tracker - determines your ovulation precisely



    Get full access to The Billion Dollar Blindspot at blog.billiondollarblindspot.com/subscribe
    41 min

About Blindspot Capital

From the publisher's feed

Exploring the big ideas, trends and investment potential in the future of women's health